• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Amy Schulman joins Polaris Partners

Amy Schulman joins Polaris Partners

July 31, 2014
CenterWatch Staff

Polaris Partners has hired biopharmaceutical executive Amy Schulman as a venture partner, based out of Boston, Mass. Schulman, who most recently was general counsel, executive vice president and business unit lead of Pfizer consumer healthcare, will apply decades of experience to the Polaris healthcare portfolio. She also will assume the role of CEO of Arsia Therapeutics, an early stage Polaris-backed company co-founded by Dr. Robert Langer and Polaris partner Alan Crane. 

Schulman is expected to assume a number of Polaris company board seats and continue to serve on the board of Cambridge-based Alnylam. At Arsia, she will work closely with Crane, who remains with the company as chairman of the board. 

At Pfizer, Schulman had a variety of executive roles including leading the nutrition business, which was sold to Nestle for $11.85 billion, and heading the consumer business, which comprised well-known brands including Advil, ChapStick and Emergen-C. She concurrently was Pfizer general counsel, managing a team of 700 legal professionals while overseeing IP, regulatory, transactional and litigation related matters.

Schulman currently is a faculty member at Harvard Business School. She also is the recipient of awards and accolades including Fortune's 50 Most Powerful Women in Business 2013, The American Lawyer's Top 50 Innovators 2013 and the Margaret Brent Women Lawyers Achievement Award from the American Bar Association in 2012. 

Before joining Pfizer, Schulman was a partner at DLA Piper, where she was a member of the board and executive policy committees, and built and led the international law firm's mass tort and class-action practice.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing